Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rroji, Merita, Figurek, Andreja, Spasovski, Goce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150959/
https://www.ncbi.nlm.nih.gov/pubmed/32106499
http://dx.doi.org/10.3390/toxins12030140
_version_ 1783521138929827840
author Rroji, Merita
Figurek, Andreja
Spasovski, Goce
author_facet Rroji, Merita
Figurek, Andreja
Spasovski, Goce
author_sort Rroji, Merita
collection PubMed
description Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.
format Online
Article
Text
id pubmed-7150959
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71509592020-04-20 Should We Consider the Cardiovascular System While Evaluating CKD-MBD? Rroji, Merita Figurek, Andreja Spasovski, Goce Toxins (Basel) Review Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers. MDPI 2020-02-25 /pmc/articles/PMC7150959/ /pubmed/32106499 http://dx.doi.org/10.3390/toxins12030140 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rroji, Merita
Figurek, Andreja
Spasovski, Goce
Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title_full Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title_fullStr Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title_full_unstemmed Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title_short Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
title_sort should we consider the cardiovascular system while evaluating ckd-mbd?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150959/
https://www.ncbi.nlm.nih.gov/pubmed/32106499
http://dx.doi.org/10.3390/toxins12030140
work_keys_str_mv AT rrojimerita shouldweconsiderthecardiovascularsystemwhileevaluatingckdmbd
AT figurekandreja shouldweconsiderthecardiovascularsystemwhileevaluatingckdmbd
AT spasovskigoce shouldweconsiderthecardiovascularsystemwhileevaluatingckdmbd

Ejemplares similares